As Big Phar­ma cir­cles RSV wag­ons, biotech re­ports mid-stage flop for its an­tivi­ral

A Phase IIb flop is cast­ing a shad­ow on one biotech’s ef­forts to take on RSV, a no­to­ri­ous­ly tough field strewn with Big Phar­ma ri­vals.

Enan­ta Phar­ma­ceu­ti­cals was plain about the topline da­ta from the RSVP tri­al, which en­rolled oth­er­wise healthy adults with com­mu­ni­ty-ac­quired res­pi­ra­to­ry syn­cy­tial virus. Its drug, EDP-938, met nei­ther the pri­ma­ry end­point of re­duc­tion in to­tal symp­tom score com­pared to place­bo, nor the sec­ondary an­tivi­ral end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER